

CITATION REPORT

List of articles citing

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older

DOI: 10.1007/s13555-019-0291-4
Dermatology and Therapy, 2019, 9, 281-297.

Source: <https://exaly.com/paper-pdf/73639630/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Risk of herpes zoster in the Japanese population with immunocompromising and chronic disease conditions: Results from a claims database cohort study, from 2005 to 2014. <i>Journal of Dermatology</i> , 2020 , 47, 236-244	1.6	4
5	Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 17, 3735-3746	4.4	2
4	Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. <i>Journal of Medical Economics</i> , 2022 , 25, 26-37	2.4	4
3	Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults. <i>Dermatology and Therapy</i> , 2022 , 12, 1447-1467	4	2
2	How large could the public health impact of introducing recombinant zoster vaccination for people aged 50 years in five Latin American countries be?. 2023 , 19,		0
1	Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review. 2023 , 19,		0